BMBrent R. Martin

Brent R. Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brent R. Martin has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models

    by Raymond A. Pagliarini, Jack A. Henderson, Benjamin C. Milgram, Deanna R. Borrelli, Natasja Brooijmans, Brendan J. Hilbert, Michael R. Huff, Takahiro Ito, Gregory V. Kryukov, Brendon Ladd, et al.

  • Open Access

    Supplementary Methods1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models

    by Raymond A. Pagliarini, Jack A. Henderson, Benjamin C. Milgram, Deanna R. Borrelli, Natasja Brooijmans, Brendan J. Hilbert, Michael R. Huff, Takahiro Ito, Gregory V. Kryukov, Brendon Ladd, et al.

    Methods and method references related to crystallography and molecular dynamics

  • Open Access

    Supplementary Tables1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models

    by Raymond A. Pagliarini, Jack A. Henderson, Benjamin C. Milgram, Deanna R. Borrelli, Natasja Brooijmans, Brendan J. Hilbert, Michael R. Huff, Takahiro Ito, Gregory V. Kryukov, Brendon Ladd, et al.

    Supplementary Tables S1 through S7

  • Open Access

    STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models

    by Raymond A. Pagliarini, Jack A. Henderson, Benjamin C. Milgram, Deanna R. Borrelli, Natasja Brooijmans, Brendan J. Hilbert, Michael R. Huff, Takahiro Ito, Gregory V. Kryukov, Brendon Ladd, et al.

    Purpose: Commonly occurring oncogenic mutations in EGFR render non–small cell lung cancers sensitive to approved EGFR-targeted drugs. EGFR in-frame exon 20 insertion (ex20ins) mutants are, however, less sensitive to such drugs. The efficacy of existing medicines may in part be limited by their selectivity for ex20ins mutations relative to wild-type EGFR, which is important for epithelial tissue homeostasis. Experimental Design: We solved high-resolution crystal structures of clinically frequent ex20ins mutants to better understand how to achieve mutant-selective inhibition. Analyses of these structures demonstrate targetable ex20ins-mutant–biased dynamic protein states. To exploit these findings, we designed STX-721, an irreversible EGFR/ERBB2 ex20ins-mutant–selective inhibitor, and characterized its activity relative to clinical phase benchmarks across multiple preclinical assays. Results: Structural analyses predict that STX-721 takes advantage of ex20ins-mutant–selective dynamic states. In carefully benchmarked biochemical, biophysical, and cellular assays, STX-721 demonstrated superior ex20ins-mutant selectivity relative to other tested benchmark clinical phase compounds and achieved ex20ins-mutant–selective tumor regression in vivo. Conclusions: These data highlight that STX-721 shows a high level of mutant EGFR selectivity across human preclinical cancer models and may provide an improved clinical efficacy versus adverse event profile relative to existing drugs.


  • Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation

    by Dongyu Zhao, Zhangyuan Yin, Matthew B. Soellner, Brent R. Martin


  • Tunable Heteroaromatic Sulfones Enhance in-Cell Cysteine Profiling

    by Hashim F. Motiwala, Yu-Hsuan Kuo, Brittany L. Stinger, Bruce A. Palfey, Brent R. Martin

    Heteroaromatic sulfones react with cysteine via nucleophilic aromatic substitution, providing a mechanistically selective and irreversible scaffold for cysteine conjugation. Here we evaluate a library of heteroaromatic sulfides with different oxidation states, heteroatom substitutions, and a series of electron donating and electron-withdrawing substituents. Select substitutions profoundly influence reactivity and stability compared to conventional cysteine conjugation reagents, increasing the reaction rate by >3-orders of magnitude. The findings establish a series of synthetically accessible electrophilic scaffolds tunable across multiple tunable centers. New electrophiles and their corresponding alkyne-conjugates were profiled directly in cul-tured cells, achieving thiol saturation in a few minutes at sub-millimolar concentrations. Direct addition of desthiobiotin-functionalized probes to cultured cells simplified enrichment and elution to enable mass spectrometry discovery of >3000 reactive and/or accessible thiols labeled in their native cellular environments in a fraction of the standard analysis time. Surprisingly, only 1/2 of annotated cysteines were identified by both iodoacetamide-desthiobiotin and methylsulfonylbenzothiazole-desthiobiotin in replicate experiments, demonstrating complementary detection by mass spectrometry analysis. These probes offer advantages over existing cysteine alkylation reagents, including accelerated reaction rates, improved stability, and robust ionization for mass spectrometry applications. Overall, heteroaromatic sulfones provide modular tunability, shifted chromatographic elution times, and superior in-cell cysteine profiling for in-depth proteome-wide analysis and covalent ligand discovery.


  • Enrichment of S-Palmitoylated Proteins for Mass Spectrometry Analysis

    by Melanie Cheung See Kit, Brent R. Martin

    As the 10-year anniversary of their first introduction approaches, alkynyl fatty acids have revolutionized the analysis of S-palmitoylation dynamics, acting as functional mimics incorporated into native modification sites in cultured cells. The alkyne functional group provides a robust handle for bioorthogonal Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC) to reporter-linked azides, forming a stable conjugate for enrichment for mass spectrometry analysis or in-gel fluorescence. Importantly, metabolic labeling enables time-dependent analysis of S-palmitoylation dynamics, which can be used to profile incorporation and turnover rates across the proteome. Here we present a protocol for cell labeling, click chemistry conjugation, enrichment, and isobaric tandem mass tag labeling for quantitative mass spectrometry analysis of protein S-palmitoylation.


  • Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds

    by Erika M. Lisabeth, Dylan Kahl, Indiwari Gopallawa, Sarah E. Haynes, Sean A. Misek, Phillip L. Campbell, Thomas S. Dexheimer, Dinesh Khanna, David A. Fox, Xiangshu Jin, et al.

    A series of compounds (including CCG-1423 and CCG-203971) discovered through an MRTF/SRF-dependent luciferase screen has shown remarkable efficacy in a variety of in vitro and in vivo models, including significant reduction of melanoma metastasis and bleomycin-induced fibrosis. Although these compounds are efficacious in these disease models, the molecular target is unknown. Here, we describe affinity isolation-based target identification efforts which yielded pirin, an iron-dependent cotranscription factor, as a target of this series of compounds. Using biophysical techniques including isothermal titration calorimetry and X-ray crystallography, we verify that pirin binds these compounds in vitro. We also show with genetic approaches that pirin modulates MRTF-dependent luciferase reporter activity. Finally, using both siRNA and a previously validated pirin inhibitor, we show a role for pirin in TGF-β-induced gene expression in primary dermal fibroblasts. A recently developed analog, CCG-257081, which cocrystallizes with pirin, is also effective in the prevention of bleomycin-induced dermal fibrosis.


  • Free Radical Initiated Peptide Sequencing for Direct Site Localization of Sulfation and Phosphorylation with Negative Ion Mode Mass Spectrometry

    by Nicholas Brent Borotto, Kevin M. Ileka, Christina A. T. M. B. Tom, Brent R. Martin, Kristina Håkansson

    Tandem mass spectrometry (MS/MS) is the primary method for discovering, identifying, and localizing post-translational modifications (PTMs) in proteins. However, conventional positive ion mode collision induced dissociation (CID)-based MS/MS often fails to yield site-specific information for labile and acidic modifications due to low ionization efficiency in positive ion mode and/or preferential PTM loss. While a number of alternative methods have been developed to address this issue, most require specialized instrumentation or indirect detection. In this work, we present an amine-reactive TEMPO-based free radical initiated peptide sequencing (FRIPS) approach for negative ion mode analysis of phosphorylated and sulfated peptides. FRIPS-based fragmentation generates sequence informative ions for both phosphorylated and sulfated peptides with no significant PTM loss. Furthermore, FRIPS is compared to positive ion mode CID, electron transfer dissociation (ETD) as well as negative ion mode electron capture dissociation (niECD) and CID, both in terms of sequence coverage and fragmentation efficiency for phospho- and sulfo-peptides. Because FRIPS-based fragmentation has no particular instrumentation requirements and shows limited PTM loss, we propose this approach as a promising alternative to current techniques for analysis of labile and acidic PTMs.


  • DIA-SIFT: A Precursor and Product Ion Filter for Accurate Stable Isotope Data-Independent Acquisition Proteomics

    by Sarah E. Haynes, Jaimeen D. Majmudar, Brent R. Martin

    Quantitative mass spectrometry-based protein profiling is widely used to measure protein levels across different treatments or disease states, yet current mass spectrometry acquisition methods present distinct limitations. While data-independent acquisition (DIA) bypasses the stochastic nature of data-dependent acquisition (DDA), fragment spectra derived from DIA are often complex and challenging to deconvolve. In-line ion mobility separation (IMS) adds an additional dimension to increase peak capacity for more efficient product ion assignment. As a similar strategy to sequential window acquisition methods (SWATH), IMS-enabled DIA methods rival DDA methods for protein annotation. Here we evaluate IMS-DIA quantitative accuracy using stable isotope labeling by amino acids in cell culture (SILAC). Since SILAC analysis doubles the sample complexity, we find that IMS-DIA analysis is not sufficiently accurate for sensitive quantitation. However, SILAC precursor pairs share common retention and drift times, and both species cofragment to yield multiple quantifiable isotopic y-ion peak pairs. Since y-ion SILAC ratios are intrinsic for each quantified precursor, combined MS1 and y-ion ratio analysis significantly increases the total number of measurements. With increased sampling, we present DIA-SIFT (SILAC Intrinsic Filtering Tool), a simple statistical algorithm to identify and eliminate poorly quantified MS1 and/or MS2 events. DIA-SIFT combines both MS1 and y-ion ratios, removes outliers, and provides more accurate and precise quantitation (<15% CV) without removing any proteins from the final analysis. Overall, pooled MS1 and MS2 quantitation increases sampling in IMS-DIA SILAC analyses for accurate and precise quantitation.